There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Globus Medical Inc. (GMED) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$1.05, or -1.95%, to $52.76. The Globus Medical Inc. has recorded 123,226 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Globus Medical Completes Merger with NuVasive.
As a NYSE listed company, GMED falls under the Healthcare sector while operating within the Medical Devices industry segment. At the end of the last regular session, the stock closed at $53.81 and fluctuated between $54.01 as its day high and $52.40 as its day low. The current market capitalization of Globus Medical Inc. is $5.39B. A total of 2.96 million shares were traded on the day, compared to an average of 1.45M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, GMED has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 3 SELLs from insiders. Insiders purchased 98,417 shares during that period but sold 80,117.
In the most recent transaction, Lemaitre Dan sold 43,450 shares of GMED for 56.98 per share on May 15. After the transaction, the Director now owns 10,800 company shares. In a previous transaction on Feb 02, Pfeil Keith W sold 29,167 shares at 77.57 per share. GMED shares that SVP, Chief Financial Officer owns now total 0.
Among the insiders who sold shares, Huller Kelly disposed of 7,500 shares on Dec 01 at a per-share price of $75.00. This resulted in the SVP, GC, Corporate Secretary holding 0 shares of GMED after the transaction.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for GMED in the last 3 months, the mean price target is $67.18 with high estimates of $77.00 and low estimates of $60.00. In terms of 52-week highs and lows, GMED has a high of $80.04 and a low of $50.92.
As of this writing, GMED has an earnings estimate of $0.54 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of $0.57 per share and a lower estimate of $0.51. The company reported an EPS of $0.53 in the last quarter, which was 3.90% higher than expectations of $0.51.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. GMED’s latest balance sheet shows that the firm has $443.45M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $19.78, while its Total Shareholder’s Equity was $1.74B.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GMED is Buy with a score of 3.36.